Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.58 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1982280 | 0.98 | CYP19A1 (0.56) | CYP19A1KCNMA1MPOCYP2C19PTGDR2 | |
| SCHEMBL28263864 | 0.87 | CYP19A1 (0.68) | CYP19A1PTGDR2 | |
| SCHEMBL6781834 | 0.79 | CYP19A1 (0.42) | CYP19A1MPOCYP2C19TSHRKDM4E | |
| SCHEMBL9125316 | 0.79 | CYP19A1 (0.58) | CYP19A1PTGDR2 | |
| SCHEMBL305310 | 0.79 | CYP19A1 (0.58) | CYP19A1PTGDR2 | |
| SCHEMBL8801557 | 0.79 | CYP19A1 (0.58) | CYP19A1PTGDR2 | |
| SCHEMBL6712996 | 0.79 | CYP19A1 (0.58) | CYP19A1PTGDR2 | |
| SCHEMBL12468869 | 0.79 | CYP19A1 (0.70) | CYP19A1CYP2C19CYP2D6KDM4E | |
| SCHEMBL11128645 | 0.79 | CYP19A1 (0.70) | CYP19A1CYP2C19 | |
| SCHEMBL10603653 | 0.77 | CYP19A1 (0.56) | CYP19A1CYP2C19PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | NEKTAR THERAPEUTICS (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-11834553-B2 | Alkoxylation methods | NEKTAR THERAPEUTICS (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116650424-A | Novel polypeptide formulations and therapeutic uses thereof | 鸿绪生物医药科技（北京）有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-112638426-B | Aromatic nitro-based linker, antibody conjugated drug containing linker and use of linker | 中国人民解放军军事科学院军事医学研究院 | 2023-06-16 | — | — | CN | disclosed |
| US-11672776-B2 | Multi-arm polymeric alkanoate conjugates | NEKTAR THERAPEUTICS (US) | 2023-06-13 | — | — | US | disclosed |
| EP-0018901-B1 | IMMUNOLOGICALLY ACTIVE PEPTIDYL DISACCHARIDES, METHODS OF PREPARATION AND VACCINE | MERCK & CO. INC. (US) | 1982-12-15 | — | — | EP | disclosed |
| EP-0014159-B1 | IMMUNOLOGICALLY ACTIVE DIPEPTIDYL SACCHARIDES AND METHODS OF PREPARATION | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | disclosed |
| EP-0054862-A1 | Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase | SCHERING CORPORATION (US) | 1982-06-30 | — | — | EP | disclosed |
| US-4315913-A | BACTERICIDES, VIRICIDES, PARASITICIDES VACCINE | MERCK & CO. INC. (US) | 1982-02-16 | — | — | US | disclosed |
| US-4310514-A | VACCINES | MERCK & CO., INC. (US) | 1982-01-12 | — | — | US | disclosed |
| EP-0041896-A1 | Immunologically active dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives and methods of preparation | MERCK & CO. INC. (US) | 1981-12-16 | — | — | EP | disclosed |
| EP-0039637-A1 | Immunologically active dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose derivatives and methods of preparation | MERCK & CO. INC. (US) | 1981-11-11 | — | — | EP | disclosed |
| EP-0038750-A1 | Immunologically active dipeptidyl 4-0-, 6-0-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation | MERCK & CO. INC. (US) | 1981-10-28 | — | — | EP | disclosed |
| US-4256735-A | BACTERICIDES | MERCK & CO., INC. (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0018901-A1 | Immunologically active peptidyl disaccharides, methods of preparation and vaccine | MERCK & CO. INC. (US) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | CYP19A1 4053/4885KCNMA1 345/4885MPO 3956/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | CYP19A1 4053/4885KCNMA1 345/4885MPO 3956/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | CYP19A1 4092/4885KCNMA1 337/4885MPO 3887/4885 |
| US-11672776-B2 | Multi-arm polymeric alkanoate conjugates | ALK, ALKBH3, PAICS | CYP19A1 1448/4885KCNMA1 3559/4885MPO 2429/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | CYP19A1 2591/4885KCNMA1 1233/4885MPO 2724/4885 |
| US-11834553-B2 | Alkoxylation methods | ALK, ALKBH3, SLC10A1 | CYP19A1 1066/4885KCNMA1 3974/4885MPO 422/4885 |
| US-12016952-B2 | Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition | POLM, OGG1, COPE | CYP19A1 4512/4885KCNMA1 3316/4885MPO 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.